How Lurbinectedin Interacts with Other Drugs
Lurbinectedin (Zepzelca), used for metastatic small cell lung cancer, is metabolized mainly by CYP3A4 enzymes in the liver and is a moderate inhibitor of CYP3A, P-gp, and BCRP transporters. This leads to interactions where it raises levels of certain drugs or where other drugs alter lurbinectedin exposure.[1][2]
Drugs Affected by Lurbinectedin (Inhibitor Effects)
Lurbinectedin increases exposure to:
- CYP3A4 substrates like midazolam (by 56%), potentially causing more sedation or toxicity.
- P-gp substrates such as digoxin or dabigatran, raising risks of toxicity like arrhythmias or bleeding.
- BCRP substrates including rosuvastatin, methotrexate, or sulfasalazine, which may lead to higher statin-related muscle damage or chemotherapy side effects.
Avoid strong CYP3A4 inducers (e.g., rifampin, St. John's wort) with lurbinectedin, as they cut its AUC by up to 48%, reducing efficacy. Strong CYP3A4 inhibitors (e.g., ketoconazole) boost lurbinectedin levels by 2-3 fold, requiring dose cuts.[1][3]
Common Concomitant Medications and Risks
Patients often take supportive drugs that interact:
- Antiemetics like ondansetron (CYP3A4 substrate): Monitor for QT prolongation.
- Proton pump inhibitors (e.g., omeprazole, moderate CYP2C19 inhibitor): May slightly increase lurbinectedin exposure; use alternatives if possible.
- Steroids like dexamethasone: No major issue, but watch for additive immunosuppression.
In trials, 40% of patients used CYP3A4 inhibitors without major dose adjustments.[2]
How to Manage Interactions
- Dose adjust lurbinectedin: Reduce to 2.0 mg/m² (from 3.2 mg/m²) with strong CYP3A4 inhibitors; avoid strong inducers.
- Monitor levels or effects for narrow therapeutic index drugs (e.g., warfarin, cyclosporine).
- Separate rosuvastatin by 12+ hours from lurbinectedin dosing.[1][3]
No dedicated patents on lurbinectedin interactions listed on DrugPatentWatch.com, but check for formulation patents expiring post-2030.[4]
Patient and Clinical Considerations
Hepatic impairment worsens interactions—avoid in bilirubin >1.5x ULN. Elderly patients (over 65) face higher neutropenia risk with CYP3A4-altered regimens. Report unexpected toxicities like severe fatigue or myelosuppression promptly.[2]
Sources
[1] Zepzelca Prescribing Information, Jazz Pharmaceuticals (FDA label, 2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2] Lurbinectedin pharmacokinetics review, Clin Pharmacokinet (2021). https://pubmed.ncbi.nlm.nih.gov/33555501/
[3] Drug interaction checker, FDA guidance on CYP3A. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
[4] DrugPatentWatch.com, Lurbinectedin patents. https://www.drugpatentwatch.com/p/tradename/ZEPZELCA